Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
An Improved Barcoded Oligonucleotide Primers-based Next-generation Sequencing Approach for Direct Identification of Viral Pathogens in Clinical Specimens

WANG Chun Hua¹, NIE Kai¹, ZHANG Yi¹, WANG Ji¹, ZHOU Shuai Feng¹,², LI Xin Na¹, ZHOU Hang Yu¹, QI Shun Xiang³,#, and MA Xue Jun¹,#

1. Key Laboratory for Medical Virology, National Health and Family Planning Commission, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 2. Center for Disease Prevention and Control of Hunan Province, Changsha 410005, Hunan, China; 3. Institute for Viral Disease Control and Prevention, Center for Disease Control and Prevention of Hebei, Shijiazhuang 050000, Hebei, China

Abstract

Objective  To provide a feasible and cost-effective next-generation sequencing (NGS) method for accurate identification of viral pathogens in clinical specimens, because enormous limitations impede the clinical use of common NGS, such as high cost, complicated procedures, tremendous data analysis, and high background noise in clinical samples.

Methods  Viruses from cell culture materials or clinical specimens were identified following an improved NGS procedure: reduction of background noise by sample preprocessing, viral enrichment by barcoded oligonucleotide (random hexamer or non-ribosomal hexanucleotide) primer-based amplification, fragmentation-free library construction and sequencing of one-tube mixtures, as well as rapid data analysis using an in-house pipeline.

Results  NGS data demonstrated that both barcoded primer sets were useful to simultaneously capture multiple viral pathogens in cell culture materials or clinical specimens and verified that hexanucleotide primers captured as many viral sequences as hexamers did. Moreover, direct testing of clinical specimens using this improved hexanucleotide primer-based NGS approach provided further detailed genotypes of enteroviruses causing hand, foot, and mouth disease (HFMD) and identified other potential viruses or differentiated misdiagnosis events.

Conclusion  The improved barcoded oligonucleotide primer-based NGS approach is simplified, time saving, cost effective, and appropriate for direct identification of viral pathogens in clinical practice.

Key words: NGS; Barcoded oligonucleotide primers; Virus identification; Clinical specimen

*This work was supported by the China Mega-Project for Infectious Disease (2016ZX10004-101, 2016ZX10004-215); Beijing Municipal Science & Technology Commission Project (D151100002115003); and Guangzhou Municipal Science & Technology Commission Project (2015B2150820).

Correspondence should be addressed to MA Xue Jun, Professor, PhD, Tel/Fax: 86-10-58900810, E-mail: maxj@ivdc.chinacdc.cn; QI Shun Xiang, Senior technologist, MS, E-mail: hbcdc999@126.com

Biographical note of the first author: WANG Chun Hua, female, born in 1988, Doctoral degree candidate, majoring in pathogen biology.
INTRODUCTION

Viruses are a cause of serious health problems in humans, both in developed and developing countries; in particular, some pathogenic viruses have a potential for rapid and global spread with high morbidity and mortality. The last 30 years of the 21st century have witnessed some outbreaks of significant public health issues caused by viruses, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003\[1-3\], swine-origin H1N1 influenza virus in 2009\[4-5\], avian-origin influenza A H7N9 virus in 2013\[6-8\], Middle East Respiratory Syndrome (MERS-CoV) in 2012\[9-12\], and Ebola virus from 2014 to 2015\[13-14\]. Therefore, accurate identification and analysis of the causative agent of viral infectious disease is extremely urgent and crucial for active control and prevention of virus spread.

In recent years, next-generation sequencing (NGS) has been an emerging method for the identification of viral pathogens. It does not require a priori knowledge of potential infectious agents and is a more powerful tool than traditional viral diagnostic methods, including electron microscopy, cell culture, antigen detection, nucleic acid detection, cytology, histology, and serology\[15\]. Multiple viruses can be detected simultaneously, and novel or highly divergent viruses can be discovered and genetically characterized using NGS\[16-24\]. However, on account of the low virus abundance and high background noise in clinical specimens, the clinical application of NGS in virus detection is still limited. Moreover, other limitations, such as the relatively high cost of library preparation and sequencing, complicated and tedious procedures, as well as tremendous data processing and analysis, also hinder the widespread use of NGS in clinical practice.

At present, there are many ways to increase the signal-to-noise ratio (ratio of viral genome to host genome), such as ultracentrifugation, filtration, nuclease treatment, sequence-independent amplification (like random PCR), or a combination of these\[25\]. Particularly, a combination method of centrifugation, filtration, nuclease treatment, and random-PCR (rPCR) showed the greatest increase in the proportion of viral sequences\[26\]. In addition, rPCR is a widely used and efficient method in which reverse transcription is performed by using oligonucleotides made up of random hexamers tagged with a known sequence for the enrichment of low-abundance viral nucleic acids\[27-30\]. Recently, a substracted primer set named non-ribosomal hexanucleotides (hexanucleotides) was designed to further reduce noise for reverse transcription, and its viral enrichment ability was verified by cDNA representational difference analysis (RDA) and compared with that of random hexamers\[31\]. NGS-based evaluation of the viral enrichment abilities of both random hexamers and hexanucleotides is yet unreported. Directly pooling samples at the very beginning (without barcodes) or pooling individual libraries (with barcoded adaptors) for NGS may reduce sequencing costs, but the subsequent verification tests of the interested sample from pooled samples or the individual library construction of each pooled sample are rather laborious and time consuming. In addition, fragmented DNA or RNA libraries are always recommended to acquire much information from the original sample; however, the shear time is difficult to control because DNA or RNA originates from samples with different virus abundance and this treatment may increase the occurrence of artefactual recombination\[32\]. Moreover, the processing and analysis of tremendous NGS data is always complex, time consuming, and highly dependent on excellent professional bioinformaticians, which is impractical in many laboratories.

To address these limitations, in the present study, we describe a simplified, rapid, and relatively cost-effective NGS approach in which the barcoded random hexamer or non-ribosomal hexanucleotide primers are used in the reverse transcription step for viral enrichment followed by sample pooling of each enriched product in one tube as a single sample for fragmentation-free library construction and sequencing, and the high-throughput sequencing data are rapidly analyzed by an in-house pipeline. We demonstrate that multiple viruses can be accurately identified from cell culture materials or clinical specimens and verify that the viral enrichment abilities of both primer sets are nearly comparative in model experiments (sequencing three representative viruses). Furthermore, direct testing of clinical specimens associated with hand, foot, and mouth disease (HFMD) using this improved hexanucleotide primer-based NGS approach provides further detailed genotypes of viral pathogens and identifies other potential viruses or differentiated misdiagnosis events appearing in the clinic.
MATERIALS AND METHODS

Clinical Specimens and Ethical Approval

Influenza B virus (Flu B), Coxsackievirus A16 (CVA16), and Epstein-Barr virus (EBV) were chosen as representatives of segmental RNA virus, non-segmental RNA virus, and DNA virus, respectively. Cell culture supernatants of Flu B and EBV were kindly provided by the Key Laboratory for Medical Virology of the China CDC. The CVA16-positive sample and 20 clinical specimens were collected from pediatric patients clinically diagnosed with severe or mild HFMD in the Hebei province of China in 2015. All samples were stored at -80 °C before use and their information is listed in Table 1. In this study, patients diagnosed with HFMD who had more serious complications, including meningitis, encephalitis, cardiorespiratory failure, acute flaccid paralysis, or death, were classified as severe HFMD. Patients diagnosed with HFMD, but without any serious complications, were classified as mild HFMD.

This project was approved by the Institutional Review Boards of the Centre of Disease Control and Prevention of China and the Ethical Review Committee of the Institute for Viral Disease Control and Prevention, Center for Disease Control and Prevention of Hebei. Individual written informed consent was obtained from the parents or guardians of all participants. All methods were carried out in accordance with the approved guidelines, including any relevant details.

Sample Preprocessing and Viral Nucleic Acid Purification

Clinical specimens were thawed at 37 °C followed by preprocessing to reduce background noise as in a previously published protocol[^33]. Briefly, the viral transport medium was vortexed thoroughly and centrifuged at 1500 × g for 10 min to remove debris. Then, the supernatant was filtered through a 0.22 μm filter (Millipore) and dispersed into aliquots.

| Specimens           | Specimen Type | Clinical Diagnosis | Laboratory Diagnosis (Real-time RT-PCR) | CT Value |
|---------------------|---------------|--------------------|----------------------------------------|----------|
| Clinical specimen 1 | Stool         | Mild HFMD          | HEV                                    | 32.9     |
| Clinical specimen 2 | Stool         | Mild HFMD          | HEV                                    | 30.6     |
| Clinical specimen 3 | Stool         | Mild HFMD          | HEV                                    | 34.0     |
| Clinical specimen 4 | Rectal swabs  | Mild HFMD          | HEV                                    | 32.0     |
| Clinical specimen 5 | Rectal swabs  | Mild HFMD          | HEV                                    | 34.0     |
| Clinical specimen 6 | Stool         | Mild HFMD          | HEV                                    | 30.2     |
| Clinical specimen 7 | Throat swabs  | Mild HFMD          | HEV                                    | 29.8     |
| Clinical specimen 8 | Throat swabs  | Mild HFMD          | HEV                                    | 33.0     |
| Clinical specimen 9 | Throat swabs  | Mild HFMD          | -                                      | 36.2     |
| Clinical specimen 10| Throat swabs  | Mild HFMD          | HEV                                    | 32.0     |
| Clinical specimen 11| Stool         | Severe HFMD        | HEV                                    | 27.9     |
| Clinical specimen 12| Stool         | Severe HFMD        | HEV                                    | 28.1     |
| Clinical specimen 13| Stool         | Severe HFMD        | -                                      | 35.4     |
| Clinical specimen 14| Stool         | Severe HFMD        | HEV                                    | 26.2     |
| Clinical specimen 15| Stool         | Severe HFMD        | HEV                                    | 34.2     |
| Clinical specimen 16| Stool         | Severe HFMD        | HEV                                    | 32.8     |
| Clinical specimen 17| Stool         | Severe HFMD        | -                                      | 35.2     |
| Clinical specimen 18| Rectal swabs  | Severe HFMD        | HEV                                    | 34.1     |
| Clinical specimen 19| Throat swabs  | Severe HFMD        | EV 71                                  | 31.0     |
| Clinical specimen 20| Stool         | Severe HFMD        | -                                      | 35.7     |
frozen at -80 °C. An aliquot was treated with a cocktail of nucleases, including 10 units TURBO™ DNase (Ambion), 25 units Benzonase® nuclease (Sigma), 5 units DNase I (Takara), 2 μg RNase A (Takara), 5 units RNase T1 (Thermo Scientific), 4 units RNase One (Promega), 4 units micrococcal nuclease (New England Biolabs), and 15 units mung bean nuclease (Promega), to degrade any extracellular nucleic acids at 37 °C for 90 min. Then, viral nucleic acids were extracted from the preprocessed samples using the QIAamp Viral RNA Mini Kit (Qiagen) per the manufacturer’s instructions.

**Real-time RT-PCR**

For detection of Flu B, CVA16, or EBV, real-time RT-PCR was performed in a 50 μL reaction solution containing 5 μL RNA or DNA, 0.5 μL of each forward and reverse primers (Flu B; F, 5’-TCCTCAACT CACTCTTCAGCGG-3’, and R, 5’-CGGTGCTCTTGACCA AATTGGG-3’[34], CVA16; F, 5’-GGGAATTTCTTTAGCGTGTCG-3’, and R, 5’-CCCATCAARTCAATGTCCC-3’[35], EBV; F, 5’-AAACATTTGGCAGCAGTAAACG-3’, and R, 5’-ACTTACCAAGTGTCATAGGAGC-3’[36]) and other reagents of GoTaq® qPCR Master Mix (Promega). Thermal cycling parameters of reverse transcription were 42 °C for 15 min; denaturation at 95 °C for 10 min; and 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 30 s on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems).

For detection of clinical specimens from patients diagnosed with severe or mild HFMD, real-time RT-PCR was conducted using primer pairs and corresponding probes of HEV, EV71, and CVA16 per a previously published protocol[35]. Samples were considered positive only if threshold cycle (CT) values were < 35.

**Viral Nucleic Acid Enrichment**

Enrichment of purified viral nucleic acids was conducted by using a modified RT-PCR method. Briefly, 8 μL viral RNA was mixed with 0.5 mmol/L dNTPs and 50 pmol random hexamers or hexanucleotides tagged with known barcode sequences (A, AATCACATAGCGCTCGCGT; B, GGCA GACCCTCTGATACAGG; C, GGACTCGACTCTGTAACAG G; D, GTCTCTGTACGACGGTACG; E, GGAATGCGG CGTGACACCA; F, AACAATCTGGAACAGCAGCC; G, GGT CCAGCGCAAATCCGACT; H, ACGGTTGTGTACCCACGT CC; I, TGGCAACGTGACGGTTGGA; J, GGAAGGCAC AGCATAGCCA), which were not only used for viral nucleic acid enrichment but also for pooling and demultiplexing each sequencing viral library[37-38]. Then the mixture was heated at 70 °C for 5 min and immediately placed on ice. First-strand cDNA synthesis was performed per the SuperScript® III Reverse Transcriptase kit (invitrogen) manual. Thereafter, the second strand of cDNA was synthesized using 3’-5’ exo Klenow Fragment (New England Biolabs) followed by amplification of double-stranded cDNA using the barcode oligonucleotide and KAPA HiFi Hot Start Ready Mix PCR kit (KAPABiosystems) for enrichment of viral contents. The PCR program included 3 min of initial denaturation at 95 °C; 25 cycles of 98 °C for 20 s, 60 °C for 30 s, and 72 °C for 30 s; and a final extension at 72 °C for 3 min.

**Library Construction and Sequencing**

The enriched products were purified separately by using the MinElute Reaction Cleanup Kit (Qiagen) per the manufacturer’s specifications. Groups of 10 purified DNA samples were pooled at equal mass as one mixture for library construction (Figure 1). Briefly, a total of 500 ng (50 ng of each sample) of the mixture used as the input was placed in an end-repair reaction (Ion Plus Fragment Library kit, Life Technologies) and purified using Agencourt Ampure Beads (Beckman Coulter). Then, Ion Torrent sequencing adaptors were ligated on both ends of the pooled DNA followed by purification with an appropriate volume of Agencourt Ampure Beads to remove adapter dimers. The 290-330 bp fractions were recycled from the pooled DNA on E-Gel® SizeSelect™ 2% Agarose Gel (Invitrogen) and subjected to Agilent® 2100 Bioanalyzer analysis using an Agilent® high-sensitivity DNA kit (Agilent Technologies). The qualified library quantified by qPCR using Ion Library Quantification Kit (Life Technology) was subsequently subjected to emulsion-PCR with Ion PGM™ Template Hi-Q Kit (Life Technology) and ES enrichment with Ion PGM™ Enrichment Beads (Life Technology). Then, the recovered template-positive Ion Sphere™ Particles were loaded onto a 316v2 chip and sequenced on an Ion Torrent PGM™ sequencer using Ion Torrent Hi-Q sequencing kit (Life Technologies).

**NGS Data Processing and Analysis**

The raw sequencing data from each sequencing run were demultiplexed using vendor software (PGM) according to the barcode sequence to generate individual BAM files of each sample. Then, these files containing raw sequencing reads were directly processed and analyzed by in-house virus
identification pipeline (VIP) in a Bio-Linux operating environment. VIP, recently developed in our laboratory\cite{39}, is a one-touch computational pipeline for virus identification and discovery from metagenomic NGS data and contributes to timely virus diagnosis (10 min) in the performance of unbiased NGS data. The program run is accomplished in minutes and generates VIP reports, including virus populations, coverage statistics of certain gene or complete genome of viral pathogens, corresponding average depth of sequencing, and coverage files of read distributions on the reference viral genome.

RESULTS

Molecular Detection of Samples Using Real-time RT-PCR

Three representative virus-positive (Flu B, CVA16, and EBV) samples and 20 clinical specimens diagnosed with severe or mild HFMD were detected by real-time RT-PCR. The results showed that all the cell culture materials and CVA16 sample were confirmed positive. As shown in Table 2, the CT values of EBV and CVA16-positive sample were 30.6 and 30, respectively. Regarding Flu B-positive samples, two samples (Flu B-1 and Flu B-2) contained slightly high viral loads (CT values were 21 and 25, respectively), whereas the third one (Flu B-3) contained low viral loads (CT value was 29).

Among 20 HFMD clinical specimens, 16 samples were found to be positive with CT values < 35, of which 1 sample was confirmed positive for enterovirus 71 (EV 71) and 15 samples were found to be positive for human enterovirus (HEV). Notably, the remaining four samples tested negative, of which three originated from severe HFMD cases and one originated from a mild HFMD case (Table 1).

Figure 1. A schematic overview of viral enrichment and library construction in the improved NGS approach. Viral nucleic acid enrichment was initially performed using barcoded oligonucleotide primers (non-ribosomal hexanucleotides or random hexamers) in the reverse transcription step and each enriched product was pooled together in one tube as a single sample for subsequent fragmentation-free library construction and sequencing.
Comparison of Barcoded Primer-based NGS for Viral Detection

To evaluate the feasibility of the improved NGS approach, three of the representative viruses-positive samples (Flu B, CVA16, and EBV) described above were initially selected for sequencing following the modified procedure (Figure 1) in a model experiment. Meanwhile, the viral enrichment abilities of both hexanucleotide primers and the traditional random hexamer primers were compared in parallel based on NGS data. Viral nucleic acids of representative viruses were separately primed by barcoded hexamer or hexanucleotide primers in the first- and second-strand cDNA synthesis reaction followed by amplification of double-stranded cDNA using an oligonucleotide barcode. Thereafter, amplified products were pooled together as a single sample for fragmentation-free library construction and sequencing.

The raw sequencing data were assigned back to the original samples individually according to the barcode sequence. The total reads of individual samples after a single run ranged from 3,593 to 564,046, and the mean read length varied from 104 bp to 180 bp (Table 2). The proportion of virus-related reads among the total reads was further calculated via an in-house VIP. The results showed that the ratios of virus-related reads captured by hexanucleotide primers were higher than those captured by hexamer primers in RNA samples, whereas the ratio of virus-related reads captured by hexanucleotide primers was slightly lower than those captured by hexamer primers in EBV samples.

Furthermore, as shown in Table 2, the Flu B-related sequence reads enriched by hexanucleotides from samples with high viral loads (Flu B-1 or Flu B-2) revealed similar sequence coverage of Flu B segments 1-8 (range from 97.98% to 100%) compared with the results obtained by random hexamers (98.65%-100%). However, the reads enriched by hexanucleotides from samples with low viral loads (Flu B-3 or CVA16) achieved higher sequence coverage than the results obtained by random hexamers, as seen in segments 1-8 of Flu B (range from 43.90% to 81.56% vs. 35.52% to 60.75%) and the complete CVA16 genome (93.53% vs. 85.61%). Moreover, the EBV-related sequence reads enriched by both hexanucleotides and random hexamers covered the nearly complete sequence of the membrane protein gene of EBV (98.05% vs. 100%). These results indicate that the improved NGS method can accurately identify multiple viral pathogens from cell culture materials or clinical specimens and the hexanucleotide primer-based NGS is probably more suitable for clinical viral identification in view of the sequencing coverage of both RNA and DNA viruses.

Hexanucleotide Primer-based NGS for Identification of HFMD-associated Viral Pathogens in Clinical Specimens

To further confirm that the hexanucleotide primer-based NGS method is viable for clinical applications, all the clinical specimens from pediatric patients clinically diagnosed with mild or severe HFMD were subjected to sequencing following the hexanucleotide primer-based NGS procedure. Viral nucleic acids from each sample (20 samples in total) were enriched by using barcoded hexanucleotide primers in a reverse transcription, double-strand cDNA synthesis, and amplification reaction. After accomplishing library construction, two sequencing libraries (each containing 10 samples) were loaded onto two 316v2 chips (Life Technology) and separately sequenced on an Ion torrent PGM. The raw data from two independent sequencing runs were assigned back to the original samples according to the different barcode sequences. The total number of reads from each sample ranged from 4,355 to 379,687 and the mean read length varied from 83 bp to 179 bp (Table 3). All reads originating from each sample were used directly as input for the virus identification via VIP. The results showed that many reads mapped to HFMD-related viral pathogens (Figure 2A), of which eight samples were identified as Coxsackievirus A6, three samples were identified as Coxsackievirus B3, one sample was identified as Coxsackievirus A2, and another one was identified as EV 71. Additionally, the remaining seven clinical specimens were identified as HEV-negatives, of which four samples were also found to be negative by real-time RT-PCR.

Identification of HFMD-unrelated Viral Pathogens in Clinical Specimens

Further analysis showed that several HFMD-unrelated viral pathogens were simultaneously identified in the clinical samples. As shown in Figure 2B, reads of seven samples were assigned to members of the Anelloviridae family, which contains 11 genera. Two of these samples (sample 4 and sample 14) were found to have torque...
Table 2. NGS Data of Three Representative Viruses Respectively Enriched by Random Hexamer Primers or Non-ribosomal Hexanucleotide Primers in a Model Experiment

| Samples | Sample Type     | CT Values<sup>a</sup> | Total Reads (bp)<sup>a</sup> | Mean Read Length (bp)<sup>a</sup> | Virus-Related Reads (%)<sup>a</sup> | Mapping Reads of Gene or Complete Genome<sup>a</sup> | Coverage (%)<sup>a</sup> | Average Depth of Sequencing (x)<sup>a</sup> | Total Reads<sup>b</sup> | Mean Read Length (bp)<sup>b</sup> | Virus-Related Reads (%)<sup>b</sup> | Mapping Reads of Gene or Complete Genome<sup>b</sup> | Coverage (%)<sup>b</sup> | Average Depth of Sequencing (x)<sup>b</sup> |
|---------|----------------|------------------------|-------------------------------|----------------------------------|---------------------------------|---------------------------------|----------------|-------------------------------|-------------------|-------------------------------|---------------------------------|---------------------------------|----------------|-------------------------------|
| EBV     | Cell supernatant | 30.6                   | 174,795                       | 178                              | 30.3                            | membrane protein, 34,277        | 100            | 2771.57                       | 123,955           | 104                            | 19.8                            | membrane protein, 2,928         | 98.05            | 195.67                        |
| CVA16   | Throat swabs    | 30                     | 423,172                       | 157                              | 13.1                            | genome 35,624                   | 85.61          | 85.68                         | 187,994           | 175                            | 16.6                            | genome 700                     | 93.53            | 11.36                         |
| FluB-1  | Cell supernatant | 21                     | 564,046                       | 161                              | 9.9                             | segment 1 115,366               | 100            | 132.65                        | 183,436           | 153                            | 11.3                            | segment 1 3,680                  | 99.28            | 32.42                         |
|         |                 |                        |                               |                                  |                                 | segment 2 16,697                | 100            | 166.63                        |                                 | segment 2 3,817                  | 99.33            | 28.95                         |
|         |                 |                        |                               |                                  |                                 | segment 3 15,344                | 99.78          | 124.24                        |                                 | segment 3 3,481                  | 99.56            | 31.19                         |
|         |                 |                        |                               |                                  |                                 | segment 4 16,047                | 99.94          | 182.15                        |                                 | segment 4 5,593                  | 99.44            | 136.46                        |
|         |                 |                        |                               |                                  |                                 | segment 5 19,428                | 100            | 164.94                        |                                 | segment 5 4,609                  | 99.45            | 39.72                         |
|         |                 |                        |                               |                                  |                                 | segment 6 17,698                | 100            | 371.31                        |                                 | segment 6 4,642                  | 100              | 137.03                        |
|         |                 |                        |                               |                                  |                                 | segment 7 17,812                | 100            | 290.81                        |                                 | segment 7 4,008                  | 99.49            | 68.96                         |
|         |                 |                        |                               |                                  |                                 | segment 8 14,667                | 99.90          | 227.82                        |                                 | segment 8 3,272                  | 99.90            | 62.02                         |
| FluB-2  | Cell supernatant | 25                     | 283,155                       | 180                              | 10.9                            | segment 1 6,218                 | 99.95          | 48.88                         | 44,509            | 175                            | 12.3                            | segment 1 860                  | 99.07            | 7.63                          |
|         |                 |                        |                               |                                  |                                 | segment 2 7,142                 | 100            | 60.53                         |                                 | segment 2 1,154                  | 99.12            | 8.98                          |
|         |                 |                        |                               |                                  |                                 | segment 3 6,487                 | 99.82          | 63.50                         |                                 | segment 3 963                   | 99.34            | 8.69                          |
|         |                 |                        |                               |                                  |                                 | segment 4 6,772                 | 99.94          | 78.52                         |                                 | segment 4 904                   | 99.09            | 8.00                          |
|         |                 |                        |                               |                                  |                                 | segment 5 8,209                 | 99.94          | 114.48                        |                                 | segment 5 979                   | 99.51            | 11.07                        |
|         |                 |                        |                               |                                  |                                 | segment 6 7,405                 | 100            | 103.00                        |                                 | segment 6 1,865                  | 98.65            | 92.37                        |
|         |                 |                        |                               |                                  |                                 | segment 7 8,244                 | 98.65          | 202.54                        |                                 | segment 7 1,057                  | 97.98            | 13.33                        |
|         |                 |                        |                               |                                  |                                 | segment 8 6,430                 | 99.90          | 126.79                        |                                 | segment 8 916                   | 98.17            | 19.80                        |
| FluB-3  | Cell supernatant | 29                     | 3,593                         | 149                              | 13.9                            | segment 1 60                   | 35.52          | 0.48                          | 6,777              | 148                            | 14.7                            | segment 1 97                    | 47.59            | 0.65                          |
|         |                 |                        |                               |                                  |                                 | segment 2 60                   | 53.25          | 0.98                          |                                 | segment 2 85                    | 43.90            | 0.61                          |
|         |                 |                        |                               |                                  |                                 | segment 3 55                   | 48.02          | 0.88                          |                                 | segment 3 124                   | 58.30            | 1.14                          |
|         |                 |                        |                               |                                  |                                 | segment 4 57                   | 57.22          | 1.05                          |                                 | segment 4 136                   | 73.85            | 1.60                          |
|         |                 |                        |                               |                                  |                                 | segment 5 56                   | 36.11          | 0.45                          |                                 | segment 5 143                   | 80.20            | 2.42                          |
|         |                 |                        |                               |                                  |                                 | segment 6 72                   | 60.75          | 1.67                          |                                 | segment 6 138                   | 81.56            | 2.87                          |
|         |                 |                        |                               |                                  |                                 | segment 7 52                   | 38.73          | 0.65                          |                                 | segment 7 102                   | 60.92            | 1.20                          |
|         |                 |                        |                               |                                  |                                 | segment 8 64                   | 44.84          | 0.85                          |                                 | segment 8 101                   | 77.48            | 1.64                          |

Note. <sup>a</sup>Data obtained from viral enrichment by random hexamer primers in reverse transcription polymerase chain reaction. <sup>b</sup>Data obtained from viral enrichment by non-ribosomal hexanucleotide primers in reverse transcription polymerase chain reaction.
Figure 2. Schematic summary of the number of reads related to detailed virus subtypes. Reads obtained from 13 clinical specimens were related to causative agents of HFMD (A) and reads obtained from 10 clinical specimens were unrelated to causative agents of HFMD (B).

Table 3. HFMD-related Viral Pathogens Identified from Clinical Specimens Clinically Diagnosed with Mild or Severe HFMD Using the Improved Hexanucleotide Primer-Based NGS Approach

| Specimens      | HFMD-associated Viruses | Total Reads | Mean Read Length (bp) | Coverage (%) | Average Depth of Sequencing (×) |
|----------------|-------------------------|-------------|-----------------------|--------------|---------------------------------|
| Clinical specimen 1 | Coxsackievirus A6       | 44,541      | 176                   | 73.89        | 2.26                            |
| Clinical specimen 2 | Coxsackievirus A6       | 273,579     | 138                   | 91.44        | 12.02                           |
| Clinical specimen 3 | Coxsackievirus A6       | 56,236      | 156                   | -            | -                               |
| Clinical specimen 4 | Coxsackievirus A6       | 379,687     | 151                   | 87.34        | 45.48                           |
| Clinical specimen 5 | Coxsackievirus A6       | 8,731       | 160                   | -            | -                               |
| Clinical specimen 6 | Coxsackievirus A6       | 12,873      | 145                   | 39.18        | 1.43                            |
| Clinical specimen 7 | Coxsackievirus A6       | 6,416       | 163                   | 19.23        | 0.33                            |
| Clinical specimen 8 | Coxsackievirus B3       | 10,551      | 114                   | 19.23        | 0.33                            |
| Clinical specimen 9 | Coxsackievirus A6       | 15,487      | 162                   | -            | -                               |
| Clinical specimen 10 | Coxsackievirus B3       | 35,019      | 96                    | 21.03        | 0.31                            |
| Clinical specimen 11 | Coxsackievirus A6       | 181,450     | 168                   | 81.87        | 10.26                           |
| Clinical specimen 12 | Coxsackievirus A2       | 298,943     | 164                   | 58.13        | 15.96                           |
| Clinical specimen 13 | Coxsackievirus A6       | 17,672      | 151                   | -            | -                               |
| Clinical specimen 14 | Coxsackievirus A6       | 108,432     | 179                   | 96.11        | 13.93                           |
| Clinical specimen 15 | Coxsackievirus B3       | 33,690      | 153                   | 42.91        | 0.80                            |
| Clinical specimen 16 | Coxsackievirus A6       | 17,959      | 134                   | 34.24        | 1.05                            |
| Clinical specimen 17 | Coxsackievirus A6       | 9,242       | 129                   | -            | -                               |
| Clinical specimen 18 | Coxsackievirus A6       | 4,572       | 115                   | -            | -                               |
| Clinical specimen 19 | Coxsackievirus A6       | 4,355       | 83                    | 2.07         | 0.02                            |
| Clinical specimen 20 | Coxsackievirus A6       | 4,557       | 109                   | -            | -                               |
teno mini virus (TTMV)-related sequences, two of these samples (sample 6 and sample 11) were found to have both TTMV- and torque teno virus (TTV)-related sequences, a single sample (sample 15) was found to be positive for both TTMV and torque teno like midi virus (TTMDV), and another two samples (sample 12 and sample 13) were found to be positive for TTMV, TTV, and TTMDV. Notably, clinical specimen 13 contained significant numbers of reads with 93.71% of coverage on reference complete genome of TTMV 4 (Figure 3A). This sample was subsequently confirmed positive by nest RT-PCR using universal primer pairs[41] (data not shown).

Interestingly, reads of several samples were assigned to bluetongue virus and human herpesvirus, of which clinical specimen 2 and clinical specimen 14 were found to have sequences related to three human herpesvirus types. Notably, clinical specimen 3 and clinical specimen 12 tested positive for bluetongue virus with 71.69% of coverage of the PSMCH1 gene or 76.20% of coverage of the 5'-UTR of the genome, in which the latter was simultaneously co-detected with the presence of TTV, TTMV, TTMDV, and Coxsackievirus A2. Most probably, this severe patient (clinical specimen 12) was infected by multiple viral pathogens.

Furthermore, it is worth mentioning that clinical specimen 9 was found to be positive for measles virus with 77.50% coverage of the reference complete genome (Figure 3B). The interesting part is that the sample was diagnosed as mild HFMD in the clinic, but HFMD-associated viral pathogens tested negative by real-time RT-PCR (Table 1). This sample was subsequently verified by real-time RT-PCR using measles virus-specific primer pairs (MF, 5'-TCAGTAGAGGCGTTGGACCC-3'; MR, 5'-GGCCGGTTTCTCTG TAGCT-3')[42] with a Ct value of 23.9. The complete genome sequence of the measles virus has since been assembled combining NGS data and Sanger sequencing data in our laboratory (data not shown). Meanwhile, the complete genome sequence of the measles virus was used for phylogenetic analysis conducted by the neighbour-joining method using MEGA 5.0 software[43] with a bootstrap value of 1,000. As shown in Figure 4, this measles virus was clustered to a branch of the phylogenetic tree together with measles virus strain genotype H1.

**DISCUSSION**

NGS is becoming a robust tool to identify and characterize viral pathogens in samples. However,
An improved next-generation sequencing for virus identification

There are some advantages of the improved NGS approach. Firstly, the procedure of library construction was simplified without the shearing step. In brief, as shown in common whole genome sequencing (WGS)\cite{30,44}, Virus Discovery based on cDNA Amplified Fragment Length Polymorphism (VIDISCA)-combined NGS\cite{45} or virocap-combined NGS\cite{16,46}, these NGS protocols for library construction are usually tedious, laborious, and time consuming because every sample must be processed individually in the entire workflow. In contrast, in the improved NGS protocol, every 10 enriched products from 10 independent samples are pooled together in one tube and the mixture is regarded as a single sample for downstream processing, including end-repair, adapter ligation, size selection, library quantity, and sequencing (Figure 1). Importantly, the improved NGS data obtained from a fragmentation-free library may conserve the natural content of the original samples and reveal factual viral pathogen information. Some artefactual recombination may be introduced into the sheared library regardless of the enzyme digestion or sonication system used for library fragmentation\cite{32}. Moreover, artificial recombination in NGS generates sequence chimeras, which can affect NGS data analysis by computational pipelines to estimate nucleotide polymorphism frequency or species population diversity and generate incorrect de novo genome assembly\cite{47-48}. Secondly, the improved NGS approach is greatly time saving, labor saving, and cost effective. Compared with the conventional protocol (samples were processed individually throughout the NGS procedure, construction of the fragmented sequencing library was always preferred, tremendous NGS data were analyzed depending on professional bioinformaticians using expensive hardware configurations or commercial software), and the improved method spent 1/10 of the time and cost 1/10 of the capital to process a sequencing library originating from 10 independent samples. Furthermore, NGS data analysis by using in-house VIP saves further time and cost in that VIP needs minimum hardware configurations and can run on a common desktop personal computer with a 3.4 GHz Intel Core i7-4770 and 16 GB of RAM (running Ubuntu 14.04 LTS), and it can be easily manipulated by someone without a background in bioinformatics. Notably, in a practical application, VIP was utilized to analyze NGS data of one unknown sample from a severe Dengue outbreak in Guangzhou, demonstrating that VIP has contributed to timely virus diagnosis (-10 min), allowing detailed virus information to be obtained in acutely ill patients, and has the potential to perform in unbiased NGS-based clinical studies that demand a short turnaround time\cite{39}. In general, the improved approach took approximately 20 h for viral pathogens analysis of 10 samples, comprising 1.5 h for RNA extraction; 4.5 h for viral enrichment; 3 h for library construction; 8.75 h for emulsion PCR, ES, and sequencing; and 2.25 h for data analysis. Therefore, the improved NGS approach combined with in-house VIP is suitable for rapid identification of viral pathogens in clinical application, especially in emerging viral outbreaks when many samples await detection.

Initially, as model experiments, the improved NGS approach was adopted to compare the viral enrichment abilities of random hexamers and non-ribosomal hexanucleotides through reverse transcription followed by PCR and sequencing using different samples containing known viruses with different viral loads. The data from one EBV sample, Flu B samples (three different viral loads), and one CVA16 sample showed that the hexanucleotides are comparable to the traditional random hexamers in the sequence performance of EBV and Flu B with high viral loads (CT values 21 or 25), because both reads of EBV and Flu B covered the nearly complete sequence of EBV membrane protein and Flu B segments 1-8 (Table 2). On the contrary, random hexamers are slightly inferior to hexanucleotides in the coverage of the complete CVA16 genome and Flu B segments 1-8 in samples with low viral loads (CT values 30 and 29 for CVA16 and FluB, respectively). These results indicate that sequence-independent amplification by barcoded oligonucleotide primers combined with the improved NGS approach can work efficiently to directly detect viral pathogens in cell culture materials and clinical specimens. Moreover, for RNA viral samples, the ratios of virus-related reads originating from hexanucleotide-enriched samples are higher than those originating from random hexamer-enriched samples (Table 2), which is consistent with the results of Endoh et al. using the
Viral co-infection was detected by NGS, and though apart from HFMD-associated viruses. For instance, pathogens unrecognized by specific real-time RT-PCR information (data not shown), and other viral these samples contain bacteria, bacteriophage, host information (data not shown), and other viral pathogens unrecognized by specific real-time RT-PCR apart from HFMD-associated viruses. For instance, viral co-infection was detected by NGS, and though few viral sequences were captured, there were enough for identification, such as TTV, TTMV, TTMDV, bluetongue virus, and human herpesvirus in HFMD-positive samples. Interestingly, TTV, TTMV, and TTMDV were also widely found in other diseases, especially viral hepatitis, asthma, and severe lower respiratory tract infections. Here, TTV or TTMV single or dual infection were found in two samples of mild HFMD and TTV, TTMV, or TTMDV single or dual or triple infection were found in five samples of severe HFMD. Up to now, there is little evidence of an association between the infection of TTV, TTMV, or TTMDV and HFMD, we speculate that TTV, TTMV, or TTMDV might be responsible for causing severe HFMD or exacerbating disease progression. Additionally, clinical specimen 9, which was initially diagnosed as mild HFMD in clinic and later tested HEV negative via real-time RT-PCR, was found as measles virus positive using NGS, even though the reads assigned to measles virus appeared low, and covered only 77.50% of the complete reference genome. We suspected that the case was probably misdiagnosed by the clinician. One of the clinical characteristics in measles patients is a maculopapular rash, which is similar to the vesicular rash caused by HFMD. Thus, it is difficult to differentiate measles and HFMD at early onset. Moreover, this measles case was successfully validated via real-time RT-PCR and was further confirmed by rechecking the medical records (clinically diagnosed as measles a month later). Therefore, NGS analysis in this study demonstrated that misdiagnoses of HFMD do occur in the clinic. Nevertheless, similar to other previous studies, the shortcoming of the improved NGS approach is its low sensitivity with respect to agent-specific real-time RT-PCR assays. Here, the improved NGS approach is less sensitive than real-time RT-PCR assays, because a sample with a CT of 33 can be detected whereas one with a CT of 34 is missed, in agreement with Thorburn et al., who state that the NGS method may have a cutoff in the region of CT 32. Furthermore, the average depth of sequencing of clinical samples with low viral loads ranged from 0.02 × to 45.48 ×, far less than that of samples with high viral contents, which ranged from 48.88 × to 126.79 ×. As Lecuit et al. showed, the sensitivity of a deep-sequencing approach for detecting viruses is dependent on sequencing depth. Probably, the relative low sensitivity of the improved NGS approach is attributable to the low sequencing depth of the ultra-low viral contents of clinical
specimens. To address this problem, adopting higher throughput methods will probably increase the viral detection rate, such as using a 318v2 chip to replace the 316v2 chip or selecting a greater capacity sequencing platform, such as the Illumina MiSeq or Ion S5.

In conclusion, the improved NGS approach is a simplified, rapid and relatively cost-effective method. It could be used for simultaneous identification of multiple viral pathogens in samples including cell culture material and clinical specimens and provide detailed typing information on specific viral pathogens, as well as differentiation of misdiagnosis events appearing in the clinic.

**AUTHOR CONTRIBUTIONS STATEMENT**

XJM, KN, and CHW conceived of the idea and designed the study; CHW conducted all the experiments; SXQ collected and provided all the HFMD clinical specimens from pediatric patients. SFZ, XNL, and HYZ provided all the primers and probes for HFMD-associated viral pathogen detection and preserved all the HFMD clinical specimens. CHW, XJM, KN, YZ, and JW analyzed the NGS data. CHW wrote the manuscript and prepared all the tables and figures; XJM reviewed the manuscript; all authors approved the manuscript.

**COMPETING FINANCIAL INTERESTS**

The authors declare that they have no competing financial interests.

Received: September 19, 2016; Accepted: December 20, 2016

**REFERENCES**

1. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 2003; 348, 1967-76.
2. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003; 300, 1394-9.
3. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature, 2003; 423, 240.
4. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet, 2009; 374, 451-8.
5. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature, 2009; 459, 931-9.
6. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med, 2013; 368, 1888-97.
7. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet, 2013; 381, 1916-25.
8. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med, 2013; 368, 1862-4.
9. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis, 2013; 19, 1819-23.
10. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet, 2013; 381, 2265-72.
11. Balkhy H. The emergence of a new corona virus--MERS-CoV: hind sight is always 20/20. J Infect Public Health, 2013; 6, 317-8.
12. Kupferschmidt K. Emerging infectious diseases. Link to MERS virus underscores bats’ puzzling threat. Science, 2013; 341, 948-9.
13. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science, 2014; 345, 1369-72.
14. Park DJ, Dudas G, Wohl S, et al. Ebola Virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell, 2015; 161, 1516-26.
15. Storch GA. Diagnostic virology. Clin Infect Dis, 2000; 31, 739-51.
16. Wylie TN, Wylie KM, Herter BN, et al. Enhanced virome sequencing using targeted sequence capture. Genome Res, 2015; 12, 1910-20.
17. Zhao J, Ragupathy V, Liu J, et al. Nanomicroarray and multiplex next-generation sequencing for simultaneous identification and characterization of influenza viruses. Emerg Infect Dis, 2015; 21, 400-8.
18. Wu Q, Ding SW, Zhang Y, et al. Identification of viruses and viroids by next-generation sequencing and homology-dependent and homology-independent algorithms. Annu Rev Phytopathol, 2015; 53, 425-44.
19. He B, Zhang Y, Xu L, et al. Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China. J Virol, 2014; 88, 7070-82.
20. Yu G, Greninger AL, Isa P, et al. Discovery of a novel polyomavirus in acute diarrheal samples from children. PLoS One, 2012; 7, e49449.
21. Bialasiewicz S, McVernon J, Nolan T, et al. Detection of a divergent Parainfluenza 4 virus in an adult patient with influenza like illness using next-generation sequencing. BMC Infect Dis, 2014; 14, 275.
22. Lorusso A, Marcacci M, Ancora M, et al. Complete genome sequence of Bluetongue virus serotype 1 circulating in Italy, obtained through a fast next-generation sequencing protocol. Genome Announc, 2014; 2, 1.
23. Pessóa R, Watanabe JT, Nukui Y, et al. Molecular characterization of human T-cell lymphotropic virus type 1 full and partial genomes by Illumina massively parallel sequencing technology. PLoS One, 2014; 9, e93374.
24. Baker KS, Leggett RM, Bexfield NH, et al. Metagenomic study
of the viruses of African straw-coloured fruit bats: detection of a chiropteran poxvirus and isolation of a novel adenovirus. Virology, 2013; 441, 95-106.

25. Kohl C, Brinkmann A, Dabrowski PW, et al. Protocol for metagenomic virus detection in clinical specimens. Emerg Infect Dis, 2015; 21, 48-57.

26. Hall RJ, Wang J, Todd AK, et al. Evaluation of rapid and simple techniques for the enrichment of viruses prior to metagenomic virus discovery. J Virol Methods, 2014; 195, 194-204.

27. Froussard P. A random-PCR method (rPCR) to construct whole cDNA library from low amounts of RNA. Nucleic Acids Res, 1992; 20, 2900.

28. Froussard P. Sequence-independent, single-primer amplification (SISPA) of complex DNA populations. Mol Cell Probes, 1993; 6, 473-81.

29. Djikeng A, Halpin R, Kuzmickas R, et al. Viral genome sequencing by random priming methods. BMC genomics, 2008; 9, 5.

30. Zoll J, Rahamat-Langendoen J, About I, et al. Direct multiplexed whole genome sequencing of respiratory tract samples reveals full viral genomic information. J Clin Virol, 2015; 66, 6-11.

31. Endoh D, Mizutani T, Kirisawa R, et al. Species-independent detection of RNA virus by representational difference analysis using non-ribosomal hexanucleotides for reverse transcription. Nucleic Acids Res, 2005; 33, e65.

32. Routh A, Head SR, Oordoukhanian P, et al. ClickSeq: fragmentation-free next-generation sequencing via click ligation of adaptors to stochastically terminated 3’-Azido cDNAs. J Mol Biol, 2015; 427, 2610-6.

33. Victoria JG, Kapoor A, Dupuis K, et al. Rapid identification of known and new RNA viruses from animal tissues. PLoS Pathog, 2008; 4, e1000163.

34. Chen Y, Cui D, Zheng S, et al. Simultaneous detection of influenza A, influenza B, and respiratory syncytial viruses and subtyping of influenza A H3N2 virus and H1N1 (2009) virus by multiplex real-time PCR. J Clin Microbiol, 2011; 49, 1653-6.

35. Cui A, Xu C, Tan X, et al. The development and application of the two real-time RT-PCR assays to detect the pathogen of HFMD. Plos One, 2013; 8, e61451.

36. Markoulatos P, Georgopoulou A, Siafakas N, et al. Laboratory diagnosis of common herpesvirus infections of the central nervous system by a multiplex PCR assay. J Clin Microbiol, 2011; 12, 4426-32.

37. Victoria JG, Kapoor A, Li L, et al. Metagenomic analyses of viruses in stool samples from children with acute flaccid paralysis. J Virol, 2009; 83, 4642-51.

38. Neill JD, Bayles DO, Ridpath JF. Simultaneous rapid sequencing of multiple RNA virus genomes. J Virol Methods, 2014; 201, 68-72.

39. Li Y, Wang H, Nie K, et al. VIP: an integrated pipeline for metagenomics of virus identification and discovery. Sci Rep, 2016; 6, 23774.

40. Biagini P. Classification of TTV and related viruses (anelloviruses). Curr Top Microbiol Immunol, 2009; 331, 21-33.

41. Zhu C, Rong A, Yuan C, et al. Molecular detection of Torque teno mini virus (TTMV) in China. Virus Genes, 2012; 3, 403-7.

42. Hummel KB, Lowe L, Bellini WJ, et al. Development of quantitative gene-specific real-time RT-PCR assays for the detection of measles virus in clinical specimens. J Virol Methods, 2006; 132, 166-73.

43. Tamura K, Peterson D, Peterson N, et al. MEGAS: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011; 28, 2731-9.

44. Metzker ML. Sequencing technologies-the next generation. Nature reviews. Genetics, 2010; 11, 31-46.

45. Shaukat S, Angez M, Alam MM, et al. Identification and characterization of unrecognized viruses in stool samples of non-polio acute flaccid paralysis children by simplified VIDISET. Virol J, 2014; 11, 146.

46. Briese T, Kapoor A, Mishra N, et al. Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis. mBio 6, 2015; e01491-515.

47. Shao W, Boltz VF, Spindler JE, et al. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology, 2013; 10, 18.

48. Edgar RC, Haas BJ, Clemente JC, et al. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics, 2011; 27, 2194-200.

49. Yzèbe D, Xueref S, Baratin D, et al. TT virus. A review of the literature. Panminerva Med, 2002; 44, 167-77.

50. Pifferi M, Maggi F, Andreoli E, et al. Associations between nasal torquenovirus load and spirometric indices in children with asthma. J Infect Dis, 2005; 192, 1141-8.

51. Lysholm F, Wetterbom A, Lindau C, et al. Characterization of the viral microbiome in patients with severe lower respiratory tract infections, using metagenomic sequencing. PLoS One, 2012; 7, e30875.

52. Harvala H, Wiman Ä, Wallensten A, et al. Role of Sequencing the Measles Virus Hemmagglutinin Gene and Hypervariable Region in the Measles Outbreak Investigations in Sweden During 2013-2014. J Infect Dis, 2016; 4, 592-9.

53. Prachayangprecha S, Schapendonk CM, Koopmans MP, et al. Exploring the potential of next-generation sequencing in detection of respiratory viruses. J Clin Microbiol, 2014; 52, 3722-30.

54. Rosseel T, Scheuch M, Höper D, et al. DNase SISPA-next generation sequencing confirms Schmallenberg virus in Belgian field samples and identifies genetic variation in Europe. PLoS One, 2012; 7, e41967.

55. Thorburn F, Bennett S, Modha S, et al. The use of next generation sequencing in the diagnosis and typing of respiratory infections. J Virol, 2015; 69, 96-100.

56. Lecuit M, Elloit M. The diagnosis of infectious diseases by whole genome next generation sequencing: a new era is opening. Front. Cell Infect. Microbiol, 2014; 4, 25.